Literature reviews, generated by AI
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
Ask a question. Get a review grounded in recent research.
PubMed research · Cited sources
6 free credits, then one-time credit packs from $5.
Recent reviews characterize brain-derived neurotrophic factor (BDNF) as a central regulator of neuronal development, survival, synaptic transmission, plasticity, cognition, stress adaptation, aging, and behavior. Its principal signaling receptor is tropomyosin receptor kinase B (TrkB), while precursor and mature BDNF forms can produce distinct or opposing effects through different receptor systems. BDNF biology depends on synthesis, intracellular transport, processing, storage, release, and receptor activation, making its effects strongly dependent on cell type, brain region, developmental stage, disease context, and timing. Altered BDNF–TrkB signaling has been associated with neurodevelopmental, psychiatric, neurodegenerative, and age-related disorders, and BDNF has consequently been investigated as both a biomarker and therapeutic target. However, peripheral measurements do not reliably represent central signaling, direct BDNF delivery has important translational limitations, and epigenetic and post-transcriptional findings remain heterogeneous. The evidence most consistently supports BDNF as a mediator of neuronal and synaptic plasticity and as a component of antidepressant mechanisms, while emphasizing the need for more selective, spatially and temporally precise interventions.
Question: BDNF- PAST 5 YEARS OF REVIEWS
Read the full reviewThe supplied literature does not document a trial specifically named the “Bot/BAL Robbins trial,” “Robbin trial,” or “Robin trial.” The term “Robbin/Robbins trial” most plausibly refers to PREEMPT 1, a randomized, double-blind, placebo-controlled study of onabotulinumtoxinA for chronic migraine. In that study, treatment reduced headache and migraine days despite failure of the prespecified primary endpoint involving headache-episode frequency. Longer-term COMPEL findings supported sustained benefit over 108 weeks and suggested improvements in depression, anxiety, sleep quality, and fatigue. Alternatively, “BOT/BAL” most plausibly refers to a phase I study of botensilimab plus balstilimab in advanced sarcomas, in which response rates were notable among patients with angiosarcoma and responses were potentially durable. Other supplied publications concern botulinum toxin in cricopharyngeal dysfunction, pediatric cerebral palsy, facial paralysis, Pisa syndrome, facial-procedure complications, and nummular headache, but none identifies a Robbins trial or directly addresses a BOT/BAL Robbins study.
Question: Bot/bal Robbin trial
Read the full reviewCurrent evidence concerning the molecular evolution of sirtuin introns is limited and largely indirect. Available studies identify functional regulatory variation within a human SIRT3 intron, intronic polymorphisms associated with traits in livestock, potential contributions of introns to alternative splicing, and broad conservation or divergence of sirtuin gene architecture in selected plant and fungal species. However, the literature does not provide a family-wide comparative analysis of intron-sequence conservation, evolutionary rates, intron gain or loss, lineage-specific divergence, or selection acting specifically on intronic regions. The strongest functional evidence comes from a variable-number tandem repeat in human SIRT3 intron 5, which displays allele-specific enhancer activity and an age-related population pattern (PMID: 15676284). Other studies primarily document associations between intronic variants and phenotypic traits or describe gene-structural patterns without testing evolutionary mechanisms. Thus, sirtuin introns are plausible contributors to regulatory and functional diversification, but their broader molecular evolution remains unresolved.
Question: molecular evolution in the introns of the sirtuin family
Read the full reviewEndometrioma, also known as an ovarian endometriotic or “chocolate” cyst, is an ovarian manifestation of endometriosis characterized by endometrial-like tissue and accumulated altered blood within the ovary. It may be asymptomatic or associated with pelvic pain, dysmenorrhea, dyspareunia, infertility, recurrence, and reduced ovarian reserve. Diagnosis relies on clinical assessment and imaging, with transvaginal ultrasonography generally used first and magnetic resonance imaging helpful for complex lesions or associated disease. Management should be individualized according to symptoms, cyst characteristics, ovarian reserve, reproductive plans, previous treatment, and patient preferences. Available strategies include observation, hormonal suppression, surgery, and assisted reproductive technology. Laparoscopic cystectomy may reduce recurrence compared with drainage and coagulation or laser vaporization, but it can injure healthy ovarian tissue and diminish ovarian reserve. Consequently, fertility counseling, ovarian-sparing surgery, avoidance of unnecessary repeat procedures, and shared decision-making are central to care.
Question: Endometrioma
Read the full reviewLa farmacoterapia de la diabetes mellitus tipo 2 (DM2) busca reducir la hiperglucemia y la hemoglobina glucosilada (HbA1c), prevenir complicaciones microvasculares y cardiovasculares, preservar la función renal y limitar los efectos adversos. La selección terapéutica debe considerar la enfermedad cardiovascular aterosclerótica, la insuficiencia cardiaca, la enfermedad renal crónica, el riesgo de hipoglucemia, el peso, la función renal, la tolerabilidad, el costo y las preferencias del paciente. Aunque la metformina continúa siendo una opción inicial apropiada para muchos pacientes, los inhibidores del cotransportador de sodio-glucosa tipo 2 (SGLT2) y los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1) ocupan un lugar prioritario cuando existen objetivos cardiorrenales o de reducción ponderal. Las sulfonilureas, las tiazolidinedionas, los inhibidores de la dipeptidil-peptidasa 4 (DPP-4) y la insulina conservan indicaciones específicas, pero presentan limitaciones relacionadas con hipoglucemia, aumento de peso, retención de líquidos o eficacia moderada. El manejo debe integrar alimentación, actividad física, educación diabetológica, seguimiento periódico y decisiones compartidas.
Question: Farmacología de la diabetes mellitus tipo 2
Read the full reviewRetroperitoneal fibrosis (RPF) is an uncommon fibroinflammatory disorder characterized by inflammatory and fibrotic tissue surrounding the abdominal aorta and iliac vessels, often encasing the ureters. Ureteral obstruction may cause hydronephrosis, acute kidney injury, chronic kidney disease, or renal failure. RPF can be idiopathic or secondary to malignancy, medications, infection, surgery, radiation, atherosclerotic inflammation, or systemic immune-mediated disease. Increasing evidence identifies immunoglobulin G4–related disease (IgG4-RD) in a substantial subset of cases previously labeled idiopathic. Diagnosis relies on cross-sectional imaging, assessment of renal and inflammatory status, and biopsy when malignancy or atypical disease is suspected. Glucocorticoids remain central treatment, supplemented by urinary decompression and steroid-sparing or biologic therapies when indicated. A phase III randomized trial found that low-dose prednisone combined with methotrexate was non-inferior to standard-dose prednisone for remission induction while reducing cumulative glucocorticoid exposure. Long-term surveillance is necessary because relapse and progressive fibrosis can occur.
Question: Retroperitoneal fibrosis
Read the full reviewObstructive sleep apnea (OSA) has been associated with diabetic peripheral neuropathy, small-fiber abnormalities, autonomic dysfunction, and electrophysiologic changes involving visual pathways. However, the available evidence is predominantly observational, heterogeneous, and vulnerable to confounding by diabetes, obesity, hypertension, vascular disease, and metabolic dysfunction. A meta-analysis found higher odds of diabetic neuropathy among patients with OSA, with the clearest signal in type 1 diabetes, while other studies reported associations between OSA severity and diabetic peripheral or corneal small-fiber abnormalities. Studies of autonomic dysfunction similarly suggest greater impairment with more severe OSA, although referral bias and comorbidity substantially limit interpretation. Evidence for generalized idiopathic polyneuropathy, focal entrapment neuropathies, cranial neuropathy, and optic neuropathy remains insufficient. OSA screening may be reasonable in patients with cryptogenic or idiopathic neuropathy when clinical risk factors are present, but established causes should be evaluated first. Current evidence does not establish OSA as an independent cause of nerve injury or demonstrate that continuous positive airway pressure reverses established neuropathy.
Question: Obstructive Sleep apnea and neuropathies
Read the full reviewPTGS2, encoding cyclooxygenase-2 (COX-2), may influence pain through effects on prostaglandin production, inflammatory signaling, nociceptor activation, and neuronal sensitization. Available human evidence links PTGS2 variants with migraine susceptibility, cancer-pain severity, endometriosis-associated pain, postoperative and procedure-related pain, visceral hyperalgesia, osteoarthritis risk, headache duration, and response to COX-inhibiting analgesics. Reported variants include rs5277, rs1799964, rs5275, rs20417, rs689466, the −765G>C promoter polymorphism, and the −1195A/G promoter polymorphism. However, findings are heterogeneous, often based on small disease-specific studies, and generally do not directly measure pain thresholds, tolerance, or generalized nociceptive sensitivity. PTGS2 variation therefore remains a possible context-dependent modifier rather than an established universal biomarker of pain.
Question: PTGS2 genetic variants AND PAIN susceptibility and sensitivity
Read the full reviewPTGS2, encoding cyclooxygenase-2 (COX-2), contributes to inflammatory, neuropathic, and centrally maintained pain through prostaglandin production, particularly prostaglandin E₂ (PGE₂). COX-2-derived prostanoids sensitize peripheral nociceptors, while spinal and other central COX-2 pathways amplify nociceptive signaling and sustain hyperalgesia. Evidence from inflammatory models shows that selective COX-2 inhibition can suppress hyperalgesia even when oedema is minimally affected, supporting analgesic mechanisms beyond reduction of tissue swelling. Spinal COX-2/PGE₂ signaling also participates in diabetic neuropathy, injury-induced hyperalgesia, and centrally maintained hypersensitivity. However, the contribution of COX-2 varies with pain model, anatomical site, and treatment timing; it is especially prominent in central sensitization and early neuropathic pain, but is not required for every form of peripheral inflammatory hyperalgesia. These findings support COX-2 as an important but context-dependent analgesic target and motivate investigation of downstream PGE₂ synthases and receptors as potentially more selective alternatives to broad COX inhibition.
Question: PTGS2 AND PAIN
Read the full reviewNeuroplasticity reshapes how neural circuits represent, predict, perceive, and respond to temporal information. The supplied evidence indicates that experience-dependent plasticity can improve temporal discrimination, recalibrate subjective duration, adjust the rate of neural timekeeping, and organize the timing and sequencing of behavior. Auditory timing training is associated with neurochemical changes and improved performance in the inferior parietal cortex, implicating higher-order processes such as attention and temporal representation (PMID: 38316210). Reward-related dopamine signals may alter subjective timekeeping according to the timing of prediction errors and reward rates (PMID: 30864882). Plasticity also modifies neural integration windows, supports temporally structured activity during planning, and enables adaptation to changing information rates (PMID: 19582146; PMID: 26468192). In learning and rehabilitation, precisely timed feedback, repeated task-relevant practice, and circuit reorganization can improve the speed, consistency, and automatization of behavior (PMID: 41419090; PMID: 15831397; PMID: 42229417). However, the evidence concerns laboratory timing, neural learning, motor performance, and rehabilitation more directly than everyday scheduling or productivity. Neuroplasticity therefore provides an indirect biological basis for more adaptive temporal perception and behavioral timing rather than a demonstrated direct determinant of daily time management.
Question: how does neuroplasticity affect use of time?
Read the full review